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ABSTRACT
CD44+/CD24- or aldehyde dehydrogenase 1 (ALDH1) has been suggested 
as a potential marker for breast cancer stem cells. In the cohort of 819 patients 
with resected ER-positive breast cancer, the ‘5-year relapse group’ within 5 years 
postsurgery during adjuvant tamoxifen treatment and the ‘non-relapse group’ 
longer than 9 years postsurgery were defined. Paraffin-embedded tumor tissues 
were available in 31 patients from 5-year relapse group and 68 from the non-relapse 
group. CD44/ CD24 and ALDH1 expression was evaluated by immunohistochemical 
staining. Phenotypes of CD44/CD24 were CD44+/CD24- in one patient (1%), CD44+/
CD24+in one patient (1%), CD44-/CD24+ in 12 patients (12%), and CD44-/CD24- in 
67 patients (68%). Four patients (4%) showed ALDH1-positivity. Due to the rarity of 
CD44-positivity or ALDH1-positivity, we dichotomized the patients into CD24-positive 
status (13%, 13/99 patients) and CD24-negative status (87%, 86/99 patients) only 
based on CD24 status, and only the status of CD24 was further analyzed. CD24-
positivity was higher in the 5-year relapse group (32%) than in the non-relapse 
group (4%). CD24-positivity was associated with negative PR (P=0.026), higher N 
stage (P=0.029), and higher histologic grade (P=0.034). However, in the multivariate 
logistic regression adjusted for the known prognostic factors, CD24-positivity was 
still a significant predictive factor for 5-year relapse (hazard ratio=8.5; P=0.006). Our 
results indicated that the expression of CD24 was a significant poor prognostic factor 
in ER-positive early breast cancer treated with adjuvant tamoxifen. CD24 is worth 
further investigation as a novel biomarker for tamoxifen resistance beyond general 
aggressiveness of cancer cells.
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INTRODUCTION
Breast cancer is the most common cancer in 
women worldwide. Despite advances in detection and 
development of new treatment approaches, this disease 
has a high mortality rate due to the emergence of therapy-
resistant cancer cells. [1] This resistance phenomenon 
also applies to tamoxifen therapy. Although in estrogen 
receptor (ER)-positive breast cancer, adjuvant tamoxifen 
reduces the risk of recurrence by approximately 50%, 
[2] many patients who receive tamoxifen as an adjuvant 
therapy eventually experience disease recurrence. This 
primary or acquired resistance to tamoxifen is a serious 
clinical problem. There are at least two major explanations 
for these observations. One explanation is that all cancer 
cells acquire resistance, resulting in decreased overall 
sensitivity to therapy over time. The other explanation 
is that cells with tumorigenic potential are intrinsically 
resistant to therapy. In this case, the relative proportion of 
cells in residual tumors with tumorigenic properties would 
be expected to increase after treatment. This concept 
parallels with the cancer stem cell theory.
The cancer stem cell hypothesis holds that since this 
subpopulation of cells is exclusively able to form tumors, 
they underpin both disease recurrence and metastasis. [3] 
Therefore, cancer stem cells have potential major clinical 
significance. In subsequent studies, CD44+/CD24-/low [4] 
and aldehyde dehydrogenase (ALDH) 1 [5] were suggested 
as potential candidates for breast cancer stem cell markers. 
Recently, Li and colleagues reported that tumorigenic 
breast cancer cells expressing CD44+/CD24-/low have 
primary resistance to conventional chemotherapy and 
accordingly their proportion increases after chemotherapy. 
[6] As suggested by linkage between chemotherapy 
resistance and cancer stem cells, the associations between 
tamoxifen resistance and breast cancer stem cells can be 
proposed. Furthermore, although CD44+/CD24-/low and 
ALDH1 were suggested as potential markers for breast 
cancer stem cells, their clinicopathologic and prognostic 
significance remains controversial. [5, 7, 8]
The current study aimed to investigate the 
association between tamoxifen resistance and breast 
cancer stem cells and clinical implications of CD44/CD24 
and ALDH1, potential markers for breast cancer stem cell. 
Therefore, we evaluated the expression patterns of CD44/
CD24 and ALDH1 in ER-positive breast cancer patients 
receiving adjuvant tamoxifen.
RESULTS
Comparison of baseline clinical characteristics 
between the 5-year relapse versus non- relapse 
groups
As summarized in Table 1, all thirty-one patints 
from 5-year relapse group and 68 from the non-relapse 
group were female, and they all had invasive ductal 
carcinomas. Between the 5-year relapse group and the 
non-relapse group, there were no differences in median 
age, menopausal status, progesterone receptor (PR) and 
HER2 status, and T stage. However, the 5-year relapse 
group, showed more advanced N stage (P=0.001) and 
higher histologic grade (P=0.039) than the non-relapse 
group. The median time to relapse in the 5-year relapse 
group was 37.8 months (range, 11.3-65.9 months), and the 
median follow-up duration in the non-relapse group was 
121.4 months (range, 109.3-155.1 months).
Comparison of IHC results between the 5-year 
relapse versus non- relapse groups
Typical positive staining patterns for stem cell 
markers are demonstrated in Figure 1. Phenotypes of 
CD44/CD24 were CD44+/CD24- in one patient (1%), 
CD44+/CD24+in one patient (1%), CD44-/CD24+ in 12 
patients (12%), and CD44-/CD24- in 67 patients (68%). 
Four patients (4%) showed ALDH1-positivity. The 
representative IHC micrographs of ALDH1, CD44 and 
CD24 are shown in Figure 1. As shown in Table 2, due to 
the rarity of CD44-positivity (2.9%) or ALDH1-positivity 
(4.0%), we dichotomized the patients into CD24-positive 
status (13.1%, 13/99 patients) and CD24-negative status 
(86.9%, 86/99 patients), only based on CD24 status. 
Therefore only the status of CD24 was further analyzed 
to evaluate predictive factors for 5-year relapse. CD24-
positivity was higher in the 5-year relapse group (32.3%) 
than in the non-relapse group (4.4%; P<0.001).
Analysis of prognostic factors of 5-year relapse
To evaluate the independent prognostic factors 
of 5-year relapse, significant variables in univariate 
analysis (P<0.05) including CD24 status were entered 
into multivariate logistic regression analysis (Table 3). 
In multivariate analysis, CD24-positivity was still a 
significant predictive factor for 5-year relapse (hazard 
ratio=8.5; P=0.006) together with higher N stage. On the 
other hand, ALDH1- positivity showed a trend for 5-year 
relapse in univariate analysis (P=0.090).
When the correlation between CD24 positivity 
and clinicopathological variables was evaluated, CD24-
positivity was associated with negative PR (P=0.026), 
higher N stage (P=0.029), and higher histologic grade 
(P=0.034) in Table 4.
DISCUSSION
The current study originally intended to analyze 
potential breast cancer stem cell markers in ER-positive 
early breast cancer. Our result indicating that only very 
few patients showed potential breast cancer stem cell 
markers, CD44+/CD24- (one out of 99 patients) or 
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ALDH1 (four out of 99 patients) may be in accordance 
with previous studies of proof of concept on cancer stem 
cells. [4, 5] According to the cancer stem cell theory, 
only a small proportion of tumor cells of less than 5% 
possess self-renewal capacity and high tumorigenicity. 
These tumor-initiating cells, called cancer stem cells may 
be responsible for recurrence and metastasis. Although 
putative breast cancer stem cells have been suggested 
to express the CD44+/CD24- marker combination, [4] 
CD24 alone has been implicated in the regulation of 
tumor growth and metastasis in previous studies. [9] This 
prompted us to evaluate if single CD24 expression affects 
prognosis in adjuvant tamoxifen-treated breast cancer 
patients, instead of performing further analysis of the 
relationship between CD44+/CD24- and clinical outcome.
CD24 is a small 27 amino acid glycoprotein at the 
outer surface of the cell membrane and it is attached to 
the cell membrane by a glycosylphosphatidyl-inositol 
(GPI) anchor. Therefore, it is involved in cell adhesion. 
[10] In breast tissues, previous studies have revealed that 
CD24 expression was higher in malignant lesions than in 
benign lesions. [11, 12] Furthermore, CD24 has emerged 
as a poor prognostic factor in various human cancers [13] 
including cancers of ovary, endometrium, uterine cervix, 
stomach, colorectal, esophagus, kidney, bladder, biliary 
tract, pancreas, non-small cell lung, and prostate as well 
as breast cancer even though there are some controversies.
In this study, the CD24-positivity rate (13%) was 
lower than that in previous data (46~85%) from breast 
cancer studies including more than 100 samples, [14, 
15] which may be explained in part by the limitations of 
IHC assay itself. This means that IHC shows frequently 
inconsistent results based on the types of antibody, criteria 
for positivity, and quality of interpretation. However, in 
Table 1: Comparison of patient characteristics between the 5-year relapse versus non-relapse groups
5-year relapse (n=31) Non-relapse (n=68)
P- value
n (%) n (%)
Age
  ≤35 years 5 (16.1) 5 (7.4) 0.179
 >35 years 26 (83.9) 63 (92.6)
Menopause
 Pre- 21 (67.7) 45 (66.2) 0.878
 Post- 10 (32.3) 23 (33.8)
PR
 Negative 8 (25.8) 14 (20.6) 0.562
 Positive 23 (74.2) 54 (79.4)
HER2
 Negative 21 (67.7) 50 (73.5) 0.553
 Positive 10 (32.3) 18 (26.5)
T stage
 T1 12 (38.7) 29 (42.6) 0.712
 T2-T3 19 (61.3) 39 (57.4)
N stage
 N0 8 (25.8) 41 (60.3) 0.001
 N1 9 (29.0) 17 (25.0)
 N2-N3 14 (45.2) 10 (14.7)
Histologic grade
 I 3 (9.7) 20 (30.8) 0.039
 II-III 28 (90.3) 45 (69.2)
Abbreviation: PR, progesterone receptor.
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this study, CD24 expression was found to significantly 
correlate with 5-year relapse in ER-positive breast cancer 
patients during adjuvant tamoxifen treatment, suggesting 
that CD24 expression may reflect tamoxifen resistance.
At first glance, our data seems to be in contrast 
with current assertions that the CD44+/CD24-/low 
subpopulation with tumor-initiating properties is 
positively correlated with distant metastasis in breast 
cancer. However, there are several plausible explanations 
for such a prometastatic role of CD24 expression in human 
tumor cells. CD24 present on the cell membrane serves 
as a ligand for P-selectin, and hence, it functions as an 
adhesion molecule that enhances platelet aggregation. 
[10, 16, 17] CD24-expressing cancer cells can bind to 
P-selectin on the endothelial cells and platelets, leading 
to promotion of extravasation and metastasis of cancer 
cells. [10, 16, 17] Secondly, several studies have suggested 
that CD24 also participates in a prometastatic signaling 
pathway via a regulator such as the chemokine receptor 
CXCR4. [10, 16, 18] Thirdly, a recent study has revealed 
that CD24 suppresses the immune response through 
interaction with Siglec protein expressed on immune cells, 
[19] contributing to cancer immune escape. However, the 
exact mechanism by which CD24 results in poor prognosis 
Figure 2: Enrolled patients. The ‘5-year relapse group’ within 5 years postsurgery during adjuvant tamoxifen treatment and the ‘non-
relapse group’ longer than 9 years postsurgery were included in this study.
Figure 1: The typical staining patterns for each stem cell marker reflect their subcellular location. ALDH1, a cytosolic 
enzyme, shows cytoplasmic staining (brown). On the other hand, CD44 and CD24 are transmembrane glycoproteins which show membrano-
cytoplasmic staining (CD44 in red color, CD24 in brown color).
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in various cancers remains unknown and it needs to be 
further elucidated.
Here, the next question is whether the poor 
prognostic impact of CD24 is linked to general 
aggressiveness of cancer cells or specifically of 
tamoxifen-resistant breast cancer cells. Surowiak et al [20] 
demonstrated that only adjuvant tamoxifen-treated patients 
(n=70) showed differential prognosis according to CD24 
expression, whereas patients (n=34) without adjuvant 
tamoxifen did not show differential prognosis. Although 
the small number of patients without tamoxifen may have 
led to the lack of difference in prognosis, they found 
some clue that there may be a correlation between CD24 
expression and tamoxifen resistance. Kim et al reported 
that CD24 expression predicted poor DFS in patients 
with ER-positive tumors (n=332), and not in patients 
with ER-negative tumors (n= 312). [21] The current 
study also demonstrated a similar result as these reports. 
That is, there was a negative correlation between CD24 
expression and prognosis in ER-positive tumors treated 
with adjuvant tamoxifen. Furthermore, in this study, 
CD24-positivity more correlated with ER-positive/PR-
negative status rather than with both ER-positive and PR-
positive status, referring to the luminal B subtype which 
is known to be relatively resistant to endocrine therapy. 
In the published microarray data reanalyzed by authors, 
when MCF7 cells, which are originally ER-positive and 
tamoxifen-sensitive, acquired resistance after exposure to 
tamoxifen for several months, tamoxifen-resistant MCF7 
cells showed higher CD24 expression compared with 
tamoxifen-sensitive MCF7 cells, [22, 23] although there 
is a controversy. [24] Meanwhile, independent microarray 
Table 2: Comparison of IHC results between the 5-year relapse versus non- relapse groups
5-year relapse (n=31) Non-relapse (n=68)
P- Value
n (%) n (%)
CD24
 Negative 21 (67.7) 65 (95.6) <0.001
 Positive 10 (32.3) 3 (4.4)
CD44
 Negative 31 (100) 66 (97.1) 1.0
 Positive 0 (0) 2 (2.9)
ALDH1
 Negative 28 (90.3) 67 (98.5) 0.090
 Positive 3 (9.7) 1 (1.5)
Abbreviation: PR, progesterone receptor.
Table 3: Multivariate analysis of predictors of 5-year relapse
HR(95%CI) P-value
N stage
 N0 1
 N1 3.4 (1.0-11.7) 0.047
 N2-N3 5.4(1.6-18.4) 0.008
Histologic grade
 I 1
 II-III 2.0(0.5-8.1) 0.324
CD24
 Negative 1
 Positive 8.5(1.8-39.5) 0.006
Abbreviations: HR, hazard ratio; CI, confidence interval.
*Logistic regression.
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analyses of breast cancers showed a consistent inverse 
correlation between CD24 levels and ER status [25, 26] 
suggesting that CD24 may be decreased by ER which has 
transcriptional activity. In addition, in vitro, CD24 was 
reported to be decreased through a direct transcriptional 
effect depending on ER and histone deacetylases. [27] 
Accordingly, the authors infer that high expression of 
CD24 may result from nonsuppression by a lower level 
of ER and it is potentially associated with tamoxifen 
resistance among ER-positive tumors. As mentioned 
above, CD24 has been studied in many cancer types 
including breast cancer, suggesting a poor prognostic 
role. In this context, for the originality of our study, we 
focused on studying potential relationship between CD24 
and tamoxifen resistance, on which previous researchers 
did not give much attention. We found a meaningful novel 
signal that CD24 may be a tamoxifen-resistance marker. 
However, it is yet to be clarified whether CD24 directly 
induces tamoxifen resistance or just a predictive marker 
of tamoxifen resistance.
Regarding the limitations of the current study, this 
is a retrospective study, not prospectively designed to 
investigate tamoxifen resistance. We suppose that there 
may be a selection bias, because patients at both ends 
of the prognostic spectrum without a gray zone, which 
is the ‘5-year relapse group’ during adjuvant tamoxifen 
treatment and the ‘non-relapse group’ longer than 9 years 
postsurgery, were selected for this study. However, by 
comparing these two groups at both ends of the prognostic 
spectrum, we could identify a novel clue that prognosis 
of tamoxifen-treated patients is distinguished by CD24 
expression, which naturally requires confirmation in larger 
studies.
Table 4: Correlation between CD24 positivity and clinicopathological variables
CD24 negative (n=86) CD 24 positive (n=13)
P- value
n (%) n (%)
Age
  ≤35 years 9 (10.5) 1 (7.7) 1.0
 >35 years 77 (89.5) 12 (92.3)
Menopause
 Pre- 59 (68.6) 7 (53.8) 0.349
 Post- 27 (31.4) 6 (46.2)
PR
 Negative 16 (18.6) 6 (46.2) 0.026
 Positive 70 (81.4) 7 (53.8)
HER2
 Negative 62 (72.1) 9 (69.2) 1.0
 Positive 24 (27.9) 4 (30.8)
T stage
 T1 37 (43.0) 4 (30.8) 0.549
 T2-T3 49 (57.0) 9 (69.2)
N stage
 N0 44 (51.2) 5 (38.5) 0.029
 N1 25 (29.1) 1 (7.7)
 N2-N3 17 (19.8) 7 (53.8)
Histologic grade
 I 23 (27.7) 0 (0) 0.034
 II-III 60 (72.3) 13 (100)
Abbreviation: PR, progesterone receptor.
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In conclusion, in ER-positive early breast cancer, 
the incidences of CD44+/CD24- and ALDH1-positivity by 
IHC, which are potential breast cancer stem cell markers, 
were very low. However, the expression of CD24 was a 
significant poor prognostic factor in ER-positive early 
breast cancer treated with adjuvant tamoxifen. CD24 
is worth further investigation as a novel biomarker for 
tamoxifen resistance beyond general aggressiveness of 
cancer cells.
MATERIALS AND METHODS
Patients and samples
Cases were selected from an institutional database 
containing information on all patients operated for primary 
breast cancer at Severance Hospital, Yonsei University 
Health System (Seoul, Korea) from 1994 to 2004. In the 
cohort of 819 patients with resected ER-positive breast 
cancer and who received adjuvant tamoxifen therapy, 
86 patients relapsed within 5 years postsurgery and 27 
patients relapsed after 5 years, whereas 706 patients did 
not show recurrence at the median follow-up duration of 
77.2 months (range, 0.2–187.8 months). Of the 706 non-
relapsed patients, 181 patients had a follow-up period 
longer than 9 years. To assume both ends of the prognostic 
spectrum, the ‘5-year relapse group’ within 5 years 
postsurgery during adjuvant tamoxifen treatment and the 
‘non-relapse group’ longer than 9 years postsurgery were 
defined. Paraffin-embedded tumor tissues were available 
in 31 patients from 5-year relapse group and 68 from the 
non-relapse group and they were included in the current 
study (Figure 2). The other paraffin-embedded tumor 
tissues were damaged during 13~23 years’ storage. Tumor 
staging was performed according to TNM staging revised 
in 2002 by the American Joint Committee on Cancer.
[28] This study was approved by the Institutional Review 
Board in Severance Hospital.
Immunohistochemistry (IHC) and its scoring for 
CD44, CD24, and ALDH1
Expression of CD44, CD24, and ALDH1 was 
determined by IHC in formalin-fixed, paraffin-embedded 
surgical specimens of the 31 patients from 5-year relapse 
group and 68 from non-relapse group. Tissue microarray 
(TMA) blocks were generated with punctures in areas 
which were ensured to have >80% tumor content in each 
tumor tissue. For IHC, all paraffin sections were cut at 
4-μm  thickness,  deparaffinized  through  xylene  and 
dehydrated with graded ethanols. Heat induced antigen 
retrieval pH6 solution was used for antigen retrieval. 
Endogenous peroxidase activity was blocked by 3% H2O2 
in methanol, and primary incubations were performed with 
mouse monoclonal CD44 antibody (Thermo Scientific) at 
1:100 for 60 minutes, mouse monoclonal CD24 antibody 
(Thermo Scientific) at 1:50, and mouse monoclonal 
ALDH1 antibody (BD Transduction Laboratories) at 
1:100. Subsequently, sections were incubated with DAKO 
Env+ secondary antibody for 30 min, visualized with 
3,3-diaminobenzadine for 10 minutes for chromogenic 
development, washed and counterstained with 
hematoxylin. For CD24 and CD44, we used a Envision 
double-staining system (DAKO).
Positivity was assessed from 0 to 100% of stained 
cells with cytoplasmic or membranous staining at any 
intensity by a pathologist who did not know the clinical 
outcome. CD44 was identified by red color (new 
fuchsin) and CD24 was identified by brown color [3, 
3’-diaminobenzidine (DAB)]. ALDH1 was also identified 
by brown color (DAB). Positivities for markers were 
defined as 10% cutoff with membrano-cytoplasmic 
staining for CD44/CD24 and 5% cutoff with cytoplasmic 
staining for ALDH1, as previously reported. [21, 29, 30]
Determination of hormone receptor and human 
epidermal growth factor receptor 2 (HER2) 
status
ER (1:100; Thermo Scientific; Fremont, CA) 
and progesterone receptor (PR; 1:50; Dako, Glostrup, 
Denmark) status was determined by IHC, where positivity 
was defined as >1% of the cell population staining 
positive for the respective receptor. HER2 status was 
determined by IHC using the HercepTest (1:250; Dako) 
and scored from 0 to 3+ as previously described in the 
Herceptin trial. A HER2 IHC score of 3+ was considered 
positive, whereas cases with a HER2 IHC score of 0 to 1+ 
were regarded as negative. However, fluorescence in situ 
hybridization test using the PathVysion HER2 DNA Probe 
Kit (Abbott, IL, USA) was carried out according to the 
manufacturer’s protocol in cases with equivocal (2+) 
staining, and cases with HER2 gene-to-chromosome 17 
ratio >2 were designated as having HER2 overexpression.
Statistical considerations
Chi-square or Fisher’s exact test was used for 
comparison of categorical variables. Multivariate analyses 
of predictive factors for 5-year relapse were performed 
using a logistic regression model. All P-values were 
two-sided, and the α level was set at 0.05. All statistical 
calculations were performed using SPSS for Windows, 
version 17.0 (SPSS, Chicago, IL, USA).
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